Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Ida Hilden"'
Publikováno v:
Blood Advances, Vol 1, Iss 27, Pp 2692-2702 (2017)
Abstract: Tissue factor pathway inhibitor α (TFPIα) inhibits prothrombinase, the thrombin-generating complex of factor Xa (FXa) and factor Va (FVa), during the initiation of coagulation. This inhibition requires binding of a conserved basic region
Externí odkaz:
https://doaj.org/article/b80cab3955024d39919b18c5139417a1
Publikováno v:
Journal of Thrombosis and Haemostasis
Background The anti‐tissue factor plasma inhibitor monoclonal antibody concizumab is under clinical investigation for subcutaneous prophylaxis of hemophilia A/B (HA/HB) with or without inhibitors. Breakthrough bleeds while on concizumab prophylaxis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::054cc2fa6d278f0474c6d7a0c08473e4
https://pubmed.ncbi.nlm.nih.gov/33819375
https://pubmed.ncbi.nlm.nih.gov/33819375
Autor:
Peter Thygesen, A. Henriksen, Haisun Zhu, Mette B. Hermit, Laust Bruun Johnsen, Per Jr Greisen, Søren Lund, Henrik Rahbek-Nielsen, Stine Kjellev, Kasper Lamberth, Henrik Østergaard, Eva Johansson, Thomas Lindebo Holm, Jais Rose Bjelke, Prafull S. Gandhi, Carsten Dan Ley, Daniel Elenius Madsen, Nikolai Lorenzen, Lisbeth Moreau Andersen, Zhiru Yang, Gustav Røder, Jacob Lund, Mette Loftager, Bjarne Gram Hansen, Amalie Carnbring Bonde, Rong Zhou, Ida Hilden, Thomas Egebjerg, Karina Thorn, Morten Grønbech Rasch, Xun Li, Fabian Stavenuiter
Publikováno v:
Blood
Østergaard and colleagues report the development of a potent bispecific antibody, Mim8, which binds both activated factor IX and factor X, mimicking the propagation of coagulation by activated factor VIII. They detail biophysical, in vitro, and in v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e433ece5cb66919dedef92b8e13f3d4
https://pubmed.ncbi.nlm.nih.gov/34077951
https://pubmed.ncbi.nlm.nih.gov/34077951
Publikováno v:
Haemophilia. 23:769-776
Aims Concizumab, a humanized monoclonal antibody against tissue factor pathway inhibitor (TFPI), is being developed as a subcutaneously (s.c.) administered treatment for haemophilia. It demonstrated a concentration-dependent procoagulant effect in fu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23b85fbf14d6f30bc9d2eff1dd4b9b5c
https://doi.org/10.1111/hae.13260
https://doi.org/10.1111/hae.13260
Autor:
Susan A. Maroney, Joan Cox Gill, Ida Hilden, Alan E. Mast, Peter Thyregod, Nicholas D. Martinez, Paul E. R. Ellery
Publikováno v:
Haemophilia
Introduction Tissue factor pathway inhibitor (TFPI) is a naturally occurring anticoagulant found in plasma, where it circulates bound to lipoproteins, factor V (FV) or Protein S (PS), and in platelets. Therapeutic agents targeting TFPI are under deve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4adb6f53a21e3738f6371759ac98e468
https://pubmed.ncbi.nlm.nih.gov/31608540
https://pubmed.ncbi.nlm.nih.gov/31608540
Autor:
Brian Lauritzen, Ida Hilden
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 25(6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03e03ba5f0d143e134b6e3fcc51add59
https://pubmed.ncbi.nlm.nih.gov/31609513
https://pubmed.ncbi.nlm.nih.gov/31609513
Autor:
Donald F. Brophy, Heidi L. Holmberg, Thomas Egebjerg, Helle Demuth, Mari Enoksson, Jens Buchardt, Thomas N. Krogh, Mette S Jensen, Marianne Kjalke, Erika J. Martin, Mads Kjelgaard-Hansen, Ida Hilden, Annika Sanfridson
Publikováno v:
Journal of thrombosis and haemostasis : JTHREFERENCES. 18(1)
Background Recombinant factor VIIa (rFVIIa) enhances thrombin generation in a platelet-dependent manner; however, rFVIIa binds activated platelets with relatively low affinity. Triggering receptor expressed on myeloid cells (TREM)-like transcript (TL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::929d68c768514bf13eb8750a838bf875
https://pubmed.ncbi.nlm.nih.gov/31549480
https://pubmed.ncbi.nlm.nih.gov/31549480
Autor:
Kristoffer W. Balling, Brian Lauritzen, Janne Olling, Mads Bjelke, Cecilia Augustsson, Ida Hilden, Anne Charlotte Hegelund, Kristin L. Abel
Publikováno v:
Journal of thrombosis and haemostasis : JTH. 17(3)
Essentials Hemophilia patients on concizumab prophylaxis may need rFVIIa to treat breakthrough bleeds. Effect and safety of concizumab + rFVIIa were tested in vitro and in vivo. Concizumab + rFVIIa had no additive effects on bleeding in hemophilic ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::528632585c3f57299874fefbf22845cf
https://pubmed.ncbi.nlm.nih.gov/30614620
https://pubmed.ncbi.nlm.nih.gov/30614620
Autor:
Mette Loftager, Susan A. Maroney, Ida Hilden, Alan E. Mast, Paul E. R. Ellery, Nicholas D. Martinez, Ken Sejling
Publikováno v:
Research and practice in thrombosis and haemostasis
Background Plasma Tissue Factor Pathway Inhibitor (TFPI) circulates bound to factor V (fV) and Protein S (PS). Estrogen therapy decreases plasma TFPI and PS. TFPI, fV, and PS circulate within platelets, and are released upon activation to modulate th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63f91541902a22981da363b00943e3ba
https://pubmed.ncbi.nlm.nih.gov/29354797
https://pubmed.ncbi.nlm.nih.gov/29354797
Publikováno v:
Journal of Thrombosis and Haemostasis. 13:2041-2052
SummaryBackground Conventional coagulation factor assays are associated with certain limitations, as they do not always reflect the clinical heterogeneity of bleeding in hemophilic patients or correctly reflect the individual patient response to trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::950be16764c7a4d25f7ed69278b04978
https://doi.org/10.1111/jth.13134
https://doi.org/10.1111/jth.13134